Wall Street analysts have a “Moderate Buy” consensus on the stock. Meanwhile, AbbVie is an attractive investment option for ...

Visa and AbbVie combine durable competitive advantages ... Visa's market dominance extends beyond traditional credit card payments. The company continues to invest heavily in digital payment ...

Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

The bottom line? AbbVie's post-Humira prospects look far better than investors are giving it credit for. The dividend is rock-solid and should continue growing along with the share price over the ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

Get a refund on sales tax, or special financing, when you use the B&H Payboo Credit Card at the iconic camera and video equipment store.

Not only did AbbVie’s Skyrizi claim first place in the full-year ranking with nearly $377 million spent on 20 separate ads for the drug, according to iSpot.TV’s analysis, but, with two other ...